Compare GRML & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRML | LUNG |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 57.9M |
| IPO Year | 2022 | 2020 |
| Metric | GRML | LUNG |
|---|---|---|
| Price | $0.29 | $1.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | ★ 3.6M | 328.0K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.27 | $1.13 |
| 52 Week High | $0.55 | $3.88 |
| Indicator | GRML | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 31.38 | 54.56 |
| Support Level | $0.27 | $1.39 |
| Resistance Level | $0.44 | $1.67 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 11.11 | 54.94 |
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.